Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France.
Wilson S, Leray E, Calocer F, Rollot F, Fauvernier M, Remontet L, Launay L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, Seze J, Zephir H, Moreau T, Laplaud DA, Lebrun-Frenay C, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Arnaud C, Derache N, Branger P, Guittet L, Defer G, Dejardin O. Wilson S, et al. BMC Neurol. 2025 Oct 27;25(1):441. doi: 10.1186/s12883-025-04459-z. BMC Neurol. 2025. PMID: 41146063 Free PMC article.
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
Gavoille A, Nourredine M, Rollot F, Casey R, Mathey G, Kerbrat A, Ciron J, De Sèze J, Stankoff B, Maillart E, Ruet A, Labauge P, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanché JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Rabilloud M, Subtil F, Vukusic S. Gavoille A, et al. J Neurol Neurosurg Psychiatry. 2025 Sep 4:jnnp-2025-336762. doi: 10.1136/jnnp-2025-336762. Online ahead of print. J Neurol Neurosurg Psychiatry. 2025. PMID: 40908119 Free article.
Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis.
Hostettler IC, Ponciano A, Wilson D, Ambler G, Singhal AB, Charidimou A, Arnold CE, Ameriso SF, Eberbach F, Phan TG, Marchina S, Beitzke M, Kleinig TJ, Mourand I, Parreira S, Singhal S, Ly J, Ma HH, Geraldes R, Fonseca AC, Pinho E Melo T, Lefèvre PH, Labauge PM, Khurram A, Kumar S, Srikanth VK, Bruno VA, Rabinstein AA, Graff-Radford J, Viswanathan A, Greenberg SM, Jäger HR, Werring DJ. Hostettler IC, et al. Neurology. 2025 Sep 9;105(5):e213984. doi: 10.1212/WNL.0000000000213984. Epub 2025 Aug 20. Neurology. 2025. PMID: 40834342
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis.
Garcia A, Rodriguez S, Dugast E, Lebrun-Frenay C, Thouvenot E, de Sèze J, Le Page E, Vukusic S, Doghri I, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Le Frère F, Nicot AB, Wiertlewski S, Gourraud PA, Michel L, Berthelot L, Laplaud DA. Garcia A, et al. Ann Clin Transl Neurol. 2025 Nov;12(11):2271-2285. doi: 10.1002/acn3.70135. Epub 2025 Aug 8. Ann Clin Transl Neurol. 2025. PMID: 40781066 Free PMC article.
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.
Gavoille A, Rollot F, Casey R, Mathey G, Le Page E, Ciron J, De Sèze J, Ruet A, Maillart E, Labauge P, Zephir H, Kwiatkowski A, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Dubessy AL, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanché JP, Doghri I, Sarov-Riviere M, Hankiewicz K, Pottier C, Dos Santos A, Nifle C, Subtil F, Vukusic S; OFSEP Investigators. Gavoille A, et al. JAMA Neurol. 2025 Oct 1;82(10):994-1003. doi: 10.1001/jamaneurol.2025.2550. JAMA Neurol. 2025. PMID: 40758347
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
Gavoille A, Leray E, Marignier R, Rollot F, Casey R, Mathey G, Michel L, De Seze J, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Laplaud DA, Papeix C, Defer G, Moreau T, Berger E, Dubessy AL, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Camdessanche JP, Doghri I, Moulin S, Labeyrie C, Hankiewicz K, Dos Santos A, Pottier C, Manchon E, Tchikviladze M, Lebrun-Frenay C, Vukusic S; OFSEP investigators. Gavoille A, et al. Neurology. 2025 Aug 26;105(4):e213907. doi: 10.1212/WNL.0000000000213907. Epub 2025 Jul 30. Neurology. 2025. PMID: 40737571
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
Robin C, Rollot F, Lefort M, Casey R, Vukusic S, Mathey G, Ciron J, De Seze J, Stankoff B, Maillart E, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanche JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Nifle C, Kerbrat A, Edan G, Le Page E, Michel L; as the OFSEP Investigators. Robin C, et al. Neurology. 2025 Aug 12;105(3):e213744. doi: 10.1212/WNL.0000000000213744. Epub 2025 Jul 16. Neurology. 2025. PMID: 40669026
Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder.
Yska HAF, Golse M, Beerepoot S, Hayer S, Bergner C, de Paiva ARB, Marelli C, Palacios NJ, Osorio YL, Huiban C, Franke G, Wortmann F, Holtick U, Ayrignac X, van der Knaap MS, Schöls L, Perlbarg V, Galanaud D, de Witte MA, Wolf NI, Nguyen S, Mochel F; and the International CSF1R‐RD Working Group. Yska HAF, et al. Mov Disord. 2025 Sep;40(9):1826-1835. doi: 10.1002/mds.30282. Epub 2025 Jul 11. Mov Disord. 2025. PMID: 40646711 Free PMC article.
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.
Cohen M, Rollot F, Debouverie M, Zephir H, Vukusic S, De Seze J, Labauge P, Landes-Chateau C, Mondot L, Levraut M, Ruet A, Berger E, Laplaud D, Ciron J, Bourre B, Le Page E, Papeix C, Thouvenot E, Al Khedr A, Stankoff B, Pelletier J, Maillart E, Casez O, Moreau T, Defer G, Clavelou P, Cabre P, Moulin S, Neau JP, Zedet M, Hankiewicz K, Doghri I, Nasr HB, Pottier C, Magy L, Boulos DD, Heinzlef O, Camdessanche JP, Coustans M, Nifle C, Brassat D, Casey R, Lebrun-Frenay C; OFSEP and SFSEP study groups. Cohen M, et al. Eur J Neurol. 2025 May;32(5):e16583. doi: 10.1111/ene.16583. Eur J Neurol. 2025. PMID: 40312884 Free PMC article.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
638 results